Form 4: Potashnick Robert reports purchase transactions in COCH

Rhea-AI Filing Summary

Potashnick Robert reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 552,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 127,500 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Potashnick Robert

(Last) (First) (Middle)

C/O 4875 WHITE BEAR PARKWAY

(Street)

WHITE BEAR LAKE MN 55110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Envoy Medical, Inc. [ COCH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/12/2026		P		212,500	A	$0.4	212,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.53							(1)	02/05/2036	Class A Common Stock	15,000		15,000	D
Warrant (right to buy)	$0.4	02/12/2026		P		127,500		(2)	(3)	Class A Common Stock	127,500	$0	127,500	D
Warrant (right to buy)	$0.4	02/12/2026		P		212,500		(2)	(4)	Class A Common Stock	212,500	$0	212,500	D

Explanation of Responses:

1. Options to purchase 3,750 shares vest on 2/5/2027, and 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months.

2. Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.

3. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.

4. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.

	/s/ Andrew Nick as Attorney-in-Fact for Robert Potashnick pursuant to Power of Attorney filed herewith.	02/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Envoy Medical (COCH) disclose for its interim CFO?

Envoy Medical disclosed that interim CFO Robert Potashnick bought 212,500 Class A shares at $0.40 per share. He also acquired warrants for additional shares and holds stock options, all reported as direct beneficial ownership on the Form 4.

How many Envoy Medical (COCH) shares did the interim CFO buy and at what price?

The interim CFO bought 212,500 shares of Envoy Medical Class A common stock at $0.40 per share. This open-market purchase was reported as a direct holding, increasing his beneficial ownership in the company’s common equity.

What warrants did Envoy Medical’s interim CFO acquire according to the Form 4?

He acquired two warrant positions for 127,500 and 212,500 shares of Class A common stock at a $0.40 exercise price. The warrants themselves were reported at a price of $0 and are directly owned by the interim CFO.

When can the Envoy Medical (COCH) warrants held by the interim CFO be exercised?

The warrants become exercisable upon shareholder approval of issuing the underlying Class A shares. Until shareholders approve that issuance, the interim CFO may not exercise the warrants, even though they are already beneficially owned.

How do FDA milestones affect Envoy Medical’s Series A-1 and A-2 warrants?

The Series A-1 and A-2 warrants held by the interim CFO have expirations tied to FDA milestones for the Acclaim CI Device. They expire based on timelines after Premarket Approval application submission or approval, with two-year and five-year outer limits respectively.

What are the key terms of the stock option reported by Envoy Medical’s interim CFO?

The interim CFO holds a stock option for 15,000 shares at a $0.53 exercise price. Options to purchase 3,750 shares vest on February 5, 2027, with the remaining 11,250 shares vesting pro rata monthly over 36 months thereafter.